AstraZeneca Pharma India Limited — Important, 28-03-2025: General Updates

AstraZeneca Pharma India Limited will discontinue the manufacture and marketing of Prolonged release Isosorbide-5-mononitrate Tablets BP 30 mg and 60 mg (Imdur) effective April 1, 2025. This product is currently used for the prophylactic treatment of angina pectoris.

The decision may affect the company’s portfolio and could lead to a reassessment of market strategy in the cardiovascular segment. While this move could introduce some uncertainty, it also opens up the opportunity for AstraZeneca to focus on other therapies or products. Investors may view this as a cautious approach, reflecting a proactive alignment with market needs.